What is BFHIV's earnings per share (EPS)?

BFHIV (BFHIV) reported diluted earnings per share of $10.89 for fiscal year 2025. This represents a 98.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BFHIV Financials

BFHIV

Trailing 12 months to March 31, 2026

Revenue $3.9B +2.0% YoY

Net Income $561.0M +99.6% YoY

EPS (Diluted) $10.89 FY2025 annual

Operating Cash Flow $2.2B +21.1% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Apr 28, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed Apr 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BFHIV SEC filings page.

BFHIV (BFHIV) reported $3.9B in revenue over the twelve months to Mar 31, 2026, up 2.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BFHIV FY2025 2026-08-30

Capital-heavy balance-sheet deleveraging is occurring alongside cash generation that remains far larger than reported earnings.

FY2025 delivered an earnings recovery: net income rose 87.0% while revenue increased only 0.2%. Declining interest expense and SG&A point to financing and cost effects—not volume—as the immediate driver, while operating cash flow exceeded net income by roughly $1.6B in both FY2024 and FY2025, revealing a persistent cash-conversion gap that likely reflects accounting items or working-capital movements.

The business is balance-sheet intensive: FY2025 assets were 5.9x revenue, so leverage and funding structure matter more than a conventional sales-margin read. Debt-to-equity fell from 3.6x in FY2021 to 1.3x in FY2025 as equity rose and long-term debt declined, showing deleveraging rather than simple asset growth.

FY2025 share count was 12.8% below FY2023 while buybacks reached $313M, so per-share improvement was supported by capital returns as well as higher net income. The combination of fewer shares and restored earnings makes EPS progression less purely operational than headline profit suggests.

Financial Health Signals

Financial health score not available

BFHIV does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

7/7

BFHIV passes 7 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

4.04x

For every $1 of reported earnings, BFHIV generates $4.04 in operating cash flow ($2.1B OCF vs $518.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.0B

YoY+4.9%

QoQ+4.4%

5Y CAGR+4.9%

10Y CAGR-4.9%

BFHIV generated $1.0B in revenue in Q1 2026. This represents an increase of 4.9% from the same quarter a year earlier. Against the prior quarter it is up 4.4%.

Net Income

$181.0M

YoY+31.2%

QoQ+241.5%

5Y CAGR-8.7%

10Y CAGR+1.3%

BFHIV reported $181.0M in net income in Q1 2026. This represents an increase of 31.2% from the same quarter a year earlier. Against the prior quarter it is up 241.5%.

EPS (Diluted)

$4.15

YoY+49.3%

BFHIV earned $4.15 per diluted share (EPS) in Q1 2026. This represents an increase of 49.3% from the same quarter a year earlier.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$3.6B

YoY-13.7%

QoQ+0.9%

5Y CAGR+6.7%

10Y CAGR+14.1%

BFHIV held $3.6B in cash as of Q1 2026; long-term debt is not reported for that period.

Dividends Per Share

$0.23

YoY+9.5%

QoQ0.0%

BFHIV paid $0.23 per share in dividends in Q1 2026. This represents an increase of 9.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

40M

YoY-13.2%

QoQ-6.3%

BFHIV had 40M shares outstanding in Q1 2026. This represents a decrease of 13.2% from the same quarter a year earlier. Against the prior quarter it is down 6.3%.

Free Cash Flow

Not reported for Q1 2026.

Margins & Returns

Net Margin

17.8%

YoY+3.6pp

QoQ+12.3pp

5Y change-17.9pp

10Y change+8.3pp

BFHIV's net profit margin was 17.8% in Q1 2026, showing the share of revenue converted to profit. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.3 percentage points.

Return on Equity

5.4%

YoY+0.9pp

QoQ+3.8pp

5Y change-10.8pp

10Y change-3.7pp

BFHIV's ROE was 5.4% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Capital Allocation

Share Buybacks

$153.0M

YoY+48.5%

QoQ+24.4%

BFHIV spent $153.0M on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 48.5% from the same quarter a year earlier. Against the prior quarter it is up 24.4%.

R&D Spending

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

BFHIV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BFHIV quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$3.9B	$3.8B+0.2%	$3.8B-10.5%	$4.3B+12.1%	$3.8B+16.9%	$3.3B-0.8%	$3.3B-18.6%	$4.0B-28.5%	$5.7B+3.5%	$5.5B+9.2%	$5.0B-22.2%	$6.4B+21.4%	$5.3B+22.8%	$4.3B+18.6%	$3.6B+14.8%	$3.2B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$2.1B-22.7%	$2.7B+5.9%	$2.5B+2.7%	$2.5B-5.0%	$2.6B-31.8%	$3.8B+18.5%	$3.2B+26.3%	$2.5B+21.0%	$2.1B+16.3%	$1.8B
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$1.2B-10.4%	$1.4B-56.5%	$3.1B+4.1%	$3.0B+24.5%	$2.4B-8.1%	$2.6B+26.0%	$2.1B+17.8%	$1.8B+15.3%	$1.5B+12.7%	$1.4B
SG&A Expenses	$2.0B	$2.0B-3.5%	$2.1B-1.5%	$2.1B+168.5%	$779.0M+16.1%	$671.0M+534.8%	$105.7M-29.8%	$150.6M-7.3%	$162.5M+2.0%	$159.3M+17.5%	$135.6M-2.1%	$138.5M-2.1%	$141.5M+29.7%	$109.1M+1.0%	$108.1M+13.4%	$95.3M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	$301.0M-54.5%	$662.0M-62.3%	$1.8B+15.8%	$1.5B+32.0%	$1.1B-8.9%	$1.3B+14.9%	$1.1B0.0%	$1.1B+12.8%	$974.4M+19.9%	$812.7M
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	$485.0M-46.8%	$911.0M-59.4%	$2.2B+11.4%	$2.0B+21.3%	$1.7B-5.2%	$1.8B+24.3%	$1.4B+7.3%	$1.3B+15.2%	$1.1B+18.2%	$965.8M
Interest Expense	$822.0M	$854.0M-11.0%	$960.0M+9.2%	$879.0M+74.8%	$503.0M+31.3%	$383.0M-23.2%	$499.0M-21.8%	$638.0M+17.6%	$542.3M+19.1%	$455.4M+22.8%	$370.9M+12.3%	$330.2M+26.8%	$260.5M-14.7%	$305.5M+4.8%	$291.5M-2.4%	$298.6M
Income Tax	$101.0M	$94.0M-7.8%	$102.0M-55.8%	$231.0M+203.9%	$76.0M-69.2%	$247.0M+165.6%	$93.0M-40.4%	$156.0M-42.1%	$269.5M-8.1%	$293.3M-1.8%	$298.8M-8.4%	$326.2M+1.4%	$321.8M+8.3%	$297.2M+14.0%	$260.6M+31.1%	$198.8M
Net Income	$561.0M	$518.0M+87.0%	$277.0M-61.4%	$718.0M+222.0%	$223.0M-72.2%	$801.0M+274.3%	$214.0M-23.0%	$278.0M-71.1%	$963.1M+22.1%	$788.7M+52.4%	$517.6M-14.5%	$605.4M+17.3%	$516.1M+4.0%	$496.2M+17.5%	$422.3M+33.9%	$315.3M
EPS (Basic)	N/A	$11.07+98.4%	$5.58-61.2%	$14.39+221.9%	$4.47-72.2%	$16.09+260.0%	$4.47-16.9%	$5.38-69.4%	$17.56+23.9%	$14.17+92.3%	$7.37-17.3%	$8.91+2.2%	$8.72-13.6%	$10.09+19.5%	$8.44+35.7%	$6.22
EPS (Diluted)	—	$10.89+98.4%	$5.49-61.7%	$14.34+221.5%	$4.46-72.2%	$16.02+259.2%	$4.46-18.3%	$5.46-68.8%	$17.49+24.0%	$14.10+92.1%	$7.34-17.1%	$8.85+12.5%	$7.87+6.1%	$7.42+12.8%	$6.58+20.7%	$5.45
Diluted Shares (Avg)	N/A	48M-5.6%	50M+0.8%	50M0.0%	50M0.0%	50M+4.4%	48M-5.9%	51M-7.6%	55M-1.4%	56M-5.1%	59M-5.5%	62M-0.2%	62M-6.7%	67M+4.2%	64M+11.0%	58M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Revenue	$1.0B+4.9%	$975.0M+5.4%	$971.0M-1.2%	$929.0M-1.1%	$970.0M-2.1%	$925.0M-9.0%	$983.0M-4.7%	$939.0M-1.4%
SG&A Expenses	$472.0M-1.0%	$554.0M+3.6%	$476.0M-17.1%	$481.0M+2.6%	$477.0M-1.0%	$535.0M+3.7%	$574.0M+14.3%	$469.0M-11.5%
Interest Expense	$193.0M-14.2%	$199.0M-13.9%	$210.0M-12.5%	$220.0M-8.7%	$225.0M-9.3%	$231.0M-2.5%	$240.0M+9.6%	$241.0M+17.6%
Income Tax	$62.0M+12.7%	-$4.0M+88.6%	$8.0M-78.4%	$35.0M-25.5%	$55.0M+3.8%	-$35.0M-34.6%	$37.0M-28.8%	$47.0M+113.6%
Net Income	$181.0M+31.2%	$53.0M+562.5%	$188.0M+9300.0%	$139.0M+4.5%	$138.0M+3.0%	$8.0M-81.8%	$2.0M-98.8%	$133.0M+177.1%
EPS (Basic)	$4.19+49.1%	N/A	$4.04+7980.0%	$2.97+10.4%	$2.81+3.7%	N/A	$0.05-98.5%	$2.69+183.2%
EPS (Diluted)	$4.15+49.3%	N/A	$3.96+7820.0%	$2.94+10.5%	$2.78+3.0%	N/A	$0.05-98.5%	$2.66+180.0%
Diluted Shares (Avg)	43M-12.9%	N/A	48M-6.9%	47M-6.0%	50M-0.2%	N/A	51M+1.8%	50M-0.2%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA.

BFHIV Balance Sheet

BFHIV quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$22.7B-1.0%	$22.9B-1.1%	$23.1B-8.9%	$25.4B+16.8%	$21.7B-3.6%	$22.5B-14.9%	$26.5B-12.8%	$30.4B-1.0%	$30.7B+20.3%	$25.5B+14.2%	$22.3B+10.7%	$20.2B+52.4%	$13.2B+10.4%	$12.0B+33.6%	$9.0B
Current Assets	N/A	N/A	N/A	N/A	N/A	$19.6B-18.6%	$24.1B-2.4%	$24.7B0.0%	$24.7B+26.1%	$19.6B+20.5%	$16.3B+17.6%	$13.8B+32.8%	$10.4B+13.9%	$9.1B+38.2%	$6.6B
Cash & Equivalents	$3.6B-2.0%	$3.7B+2.5%	$3.6B-7.7%	$3.9B+27.7%	$3.0B+8.9%	$2.8B-27.8%	$3.9B+1.5%	$3.8B-7.9%	$4.1B+122.8%	$1.9B+59.2%	$1.2B+8.4%	$1.1B+11.1%	$969.8M+8.6%	$893.4M+313.2%	$216.2M
Inventory	N/A	N/A	N/A	N/A	N/A	$164.3M-24.6%	$218.0M-12.1%	$248.0M+7.5%	$230.6M-15.0%	$271.3M+19.0%	$228.0M+3.4%	$220.5M+1410.3%	$14.6M	N/A	N/A
Accounts Receivable	$148.0M+2.1%	$145.0M+0.7%	$144.0M-12.2%	$164.0M+8.6%	$151.0M-60.7%	$383.8M-14.9%	$451.1M+11.7%	$404.0M+43.3%	$282.0M-64.6%	$797.2M+12.8%	$706.5M-5.0%	$743.3M+88.3%	$394.8M+6.7%	$370.1M+23.0%	$300.9M
Goodwill	$634.0M0.0%	$634.0M0.0%	$634.0M0.0%	$634.0M0.0%	$634.0M0.0%	$634.0M-33.6%	$954.9M0.0%	$954.8M-3.8%	$992.8M+8.5%	$915.0M-76.0%	$3.8B-1.3%	$3.9B+122.7%	$1.7B-0.9%	$1.8B+20.8%	$1.4B
Total Liabilities	$19.3B-2.5%	$19.8B-1.9%	$20.2B-12.6%	$23.1B+17.7%	$19.7B-6.5%	$21.0B-15.6%	$24.9B-11.2%	$28.1B-2.7%	$28.8B+20.8%	$23.9B+18.3%	$20.2B+14.4%	$17.6B+42.3%	$12.4B+8.0%	$11.5B+30.3%	$8.8B
Current Liabilities	N/A	N/A	N/A	N/A	N/A	$10.4B-12.2%	$11.9B+3.4%	$11.5B+13.2%	$10.1B+9.9%	$9.2B+44.1%	$6.4B+1.5%	$6.3B+39.7%	$4.5B-10.3%	$5.0B+30.5%	$3.9B
Non-Current Liabilities	N/A	N/A	N/A	N/A	N/A	$10.6B-18.7%	$13.0B-21.3%	$16.6B-11.3%	$18.7B+27.7%	$14.6B+6.2%	$13.8B+21.6%	$11.3B+43.8%	$7.9B+22.3%	$6.4B+30.1%	$4.9B
Long-Term Debt	$4.3B-22.5%	$5.6B+5.0%	$5.3B-33.9%	$8.0B+7.6%	$7.4B+165.1%	$2.8B-1.6%	$2.8B-50.2%	$5.7B-5.8%	$6.1B+8.5%	$5.6B+10.6%	$5.1B+6.1%	$4.8B+70.5%	$2.8B-1.9%	$2.9B+30.7%	$2.2B
Total Equity	$3.3B+9.0%	$3.1B+4.6%	$2.9B+28.8%	$2.3B+8.6%	$2.1B+37.1%	$1.5B-4.2%	$1.6B-31.9%	$2.3B+25.7%	$1.9B+11.9%	$1.7B-17.5%	$2.0B-16.1%	$2.4B+180.0%	$855.8M+61.9%	$528.5M+200.3%	$176.0M
Retained Earnings	$1.5B+47.6%	$999.0M+30.2%	$767.0M+724.7%	$93.0M+206.9%	-$87.0M-101.8%	$4.8B-6.4%	$5.2B+3.0%	$5.0B+20.3%	$4.2B+19.2%	$3.5B+13.0%	$3.1B+21.7%	$2.5B+24.0%	$2.0B+31.9%	$1.6B+37.3%	$1.1B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Total Assets	$22.3B-0.3%	$22.7B-1.0%	$21.7B-0.1%	$21.8B-1.5%	$22.4B+0.4%	$22.9B-1.1%	$21.7B+0.6%	$22.1B+2.5%
Cash & Equivalents	$3.6B-13.7%	$3.6B-2.0%	$3.8B+9.1%	$3.8B-6.3%	$4.2B+11.2%	$3.7B+2.5%	$3.5B+2.1%	$4.1B+21.9%
Accounts Receivable	N/A	$148.0M+2.1%	N/A	N/A	N/A	$145.0M+0.7%	N/A	N/A
Goodwill	N/A	$634.0M0.0%	N/A	N/A	N/A	$634.0M0.0%	N/A	N/A
Total Liabilities	$19.0B-1.7%	$19.3B-2.5%	$18.4B-1.2%	$18.7B-1.7%	$19.3B+0.2%	$19.8B-1.9%	$18.6B-0.6%	$19.0B+0.5%
Long-Term Debt	N/A	$4.3B-22.5%	$3.8B-17.4%	$4.2B	$5.1B	$5.6B+5.0%	$4.6B+8.5%	N/A
Total Equity	$3.3B+8.4%	$3.3B+9.0%	$3.3B+6.6%	$3.2B-0.1%	$3.1B+1.2%	$3.1B+4.6%	$3.1B+8.7%	$3.2B+15.9%
Retained Earnings	$1.6B+45.9%	$1.5B+47.6%	$1.4B+42.8%	$1.3B+24.0%	$1.1B+26.5%	$999.0M+30.2%	$1.0B+36.5%	$1.0B+76.3%

Not reported in any period shown, so not listed: Current Assets, Short-Term Investments, Inventory, Long-Term Investments, Current Liabilities, Non-Current Liabilities.

BFHIV Cash Flow Statement

BFHIV quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$2.2B	$2.1B+12.5%	$1.9B-6.4%	$2.0B+7.5%	$1.8B+19.8%	$1.5B-18.1%	$1.9B+54.6%	$1.2B-55.8%	$2.8B+6.0%	$2.6B+22.2%	$2.1B+20.9%	$1.8B+30.9%	$1.3B+34.0%	$1.0B-11.5%	$1.1B+12.1%	$1.0B
Depreciation & Amortization	N/A	$80.0M-11.1%	$90.0M-22.4%	$116.0M+2.7%	$113.0M-8.1%	$123.0M-33.2%	$184.0M-26.1%	$249.0M-48.9%	$487.3M-2.1%	$497.6M-2.8%	$512.1M+4.0%	$492.2M+57.2%	$313.1M+44.9%	$216.1M+29.5%	$166.9M+9.0%	$153.2M
Stock-Based Compensation	N/A	$56.0M+3.7%	$54.0M+22.7%	$44.0M+33.3%	$33.0M+13.8%	$29.0M+38.1%	$21.0M-61.8%	$55.0M-31.9%	$80.8M+7.6%	$75.1M-1.8%	$76.5M-16.2%	$91.3M+25.9%	$72.5M+22.5%	$59.2M+17.2%	$50.5M+16.1%	$43.5M
Capital Expenditures	N/A	N/A	N/A	N/A	$68.0M-19.0%	$84.0M+55.6%	$54.0M-62.0%	$142.0M-28.9%	$199.8M-11.4%	$225.4M+8.9%	$207.0M+8.0%	$191.7M+20.8%	$158.7M+17.2%	$135.4M+16.2%	$116.5M+58.4%	$73.5M
Free Cash Flow	N/A	N/A	N/A	N/A	$1.8B+22.0%	$1.5B-20.2%	$1.8B+70.0%	$1.1B-57.9%	$2.6B+7.6%	$2.4B+23.6%	$1.9B+22.5%	$1.6B+32.3%	$1.2B+36.6%	$868.1M-14.7%	$1.0B+8.5%	$937.8M
Investing Cash Flow	-$1.7B	-$1.4B-17.3%	-$1.2B-248.4%	$788.0M+115.4%	-$5.1B-202.2%	-$1.7B-195.3%	$1.8B-38.0%	$2.9B+252.8%	-$1.9B+56.1%	-$4.3B+0.5%	-$4.3B-27.6%	-$3.4B	N/A	N/A	-$2.7B-156.7%	-$1.0B
Financing Cash Flow	-$720.0M	-$807.0M-36.3%	-$592.0M+80.8%	-$3.1B-194.5%	$3.3B+437.3%	$608.0M+114.6%	-$4.2B-1.8%	-$4.1B-236.0%	-$1.2B-130.4%	$4.0B+51.9%	$2.6B+53.4%	$1.7B	N/A	N/A	$2.2B+1922.0%	$109.3M
Dividends Paid	$40.0M	$40.0M-7.0%	$43.0M+2.4%	$42.0M-2.3%	$43.0M+2.4%	$42.0M-31.1%	$61.0M-52.0%	$127.0M+1.4%	$125.2M+8.4%	$115.5M+285.0%	$30.0M	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$363.0M	$313.0M+469.1%	$55.0M+57.1%	$35.0M+191.7%	$12.0M	$0	N/A	$976.0M+120.2%	$443.2M-20.0%	$553.7M-30.7%	$798.8M-16.1%	$951.6M+232.0%	$286.6M+24.0%	$231.1M+83.6%	$125.8M-47.8%	$240.9M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Cash Flow	$487.0M+23.9%	$568.0M+18.6%	$605.0M+32.7%	$526.0M+10.3%	$393.0M-12.1%	$479.0M-22.4%	$456.0M-27.5%	$477.0M+39.1%
Depreciation & Amortization	$19.0M-9.5%	$19.0M-13.6%	$20.0M-9.1%	$20.0M-13.0%	$21.0M-8.7%	$22.0M-8.3%	$22.0M-4.3%	$23.0M-34.3%
Stock-Based Compensation	$15.0M+15.4%	N/A	$14.0M+7.7%	$15.0M+7.1%	$13.0M-13.3%	N/A	$13.0M+30.0%	$14.0M+16.7%
Investing Cash Flow	$317.0M-54.1%	-$1.5B-11.3%	-$338.0M+40.6%	-$221.0M-812.9%	$691.0M-4.0%	-$1.4B+24.6%	-$569.0M-102.5%	$31.0M+111.0%
Financing Cash Flow	-$475.0M+15.5%	$784.0M-29.7%	-$306.0M+37.3%	-$723.0M-196.3%	-$562.0M+42.4%	$1.1B-20.1%	-$488.0M-60.5%	-$244.0M+28.9%
Dividends Paid	$10.0M0.0%	$10.0M-9.1%	$10.0M0.0%	$10.0M-9.1%	$10.0M-9.1%	$11.0M+10.0%	$10.0M-9.1%	$11.0M0.0%
Share Buybacks	$153.0M+48.5%	$123.0M+179.5%	$40.0M	$47.0M	$103.0M+836.4%	$44.0M	$0-100.0%	$0

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.

BFHIV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BFHIV quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	N/A	N/A	N/A	N/A	37.0%+3.4pp	33.6%-21.6pp	55.2%+0.3pp	54.9%+6.8pp	48.1%+7.4pp	40.8%+1.5pp	39.3%-1.7pp	41.0%-1.2pp	42.1%-0.8pp	42.9%
Operating Margin	N/A	N/A	N/A	N/A	N/A	9.1%-7.2pp	16.4%-14.7pp	31.0%+3.3pp	27.7%+4.8pp	22.9%+3.4pp	19.6%-1.1pp	20.7%-4.7pp	25.4%-1.3pp	26.8%+1.2pp	25.6%
Net Margin	13.5%+6.2pp	7.2%-9.5pp	16.7%+10.9pp	5.8%-18.6pp	24.5%+18.0pp	6.5%-0.4pp	6.9%-10.1pp	17.0%+2.6pp	14.4%+4.1pp	10.3%+0.9pp	9.4%-0.3pp	9.7%-1.8pp	11.5%-0.1pp	11.6%+1.7pp	9.9%
Return on Equity	15.6%+6.5pp	9.1%-15.5pp	24.6%+14.8pp	9.8%-28.5pp	38.4%+24.3pp	14.1%-3.4pp	17.5%-23.8pp	41.3%-1.2pp	42.5%+11.3pp	31.2%+1.1pp	30.1%+8.6pp	21.5%-36.4pp	58.0%-21.9pp	79.9%-99.3pp	179.2%
Return on Assets	2.3%+1.1pp	1.2%-1.9pp	3.1%+2.2pp	0.9%-2.8pp	3.7%+2.7pp	0.9%-0.1pp	1.1%-2.1pp	3.2%+0.6pp	2.6%+0.5pp	2.0%-0.7pp	2.7%+0.1pp	2.6%-1.2pp	3.8%+0.2pp	3.5%0.0pp	3.5%
Current Ratio	N/A	N/A	N/A	N/A	N/A	1.88-0.1x	2.03-0.1x	2.15-0.3x	2.43+0.3x	2.12-0.4x	2.54+0.3x	2.19-0.1x	2.30+0.5x	1.81+0.1x	1.71
Debt-to-Equity	1.29-0.5x	1.820.0x	1.81-1.7x	3.540.0x	3.57+1.7x	1.840.0x	1.79-0.7x	2.46-0.8x	3.28-0.1x	3.38+0.9x	2.52+0.5x	1.99-1.3x	3.27-2.1x	5.40-7.0x	12.41
Asset Turnover	0.170.0x	0.170.0x	0.190.0x	0.150.0x	0.150.0x	0.150.0x	0.150.0x	0.190.0x	0.180.0x	0.20-0.1x	0.290.0x	0.26-0.1x	0.330.0x	0.300.0x	0.35
FCF Margin	N/A	N/A	N/A	46.5%+1.9pp	44.6%-10.9pp	55.5%+28.9pp	26.6%-18.5pp	45.1%+1.7pp	43.4%+5.1pp	38.3%+14.0pp	24.3%+2.0pp	22.4%+2.3pp	20.1%-7.9pp	28.0%-1.6pp	29.5%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Net Margin	17.8%+3.6pp	5.4%+4.6pp	19.4%+19.2pp	15.0%+0.8pp	14.2%+0.7pp	0.9%-3.5pp	0.2%-16.4pp	14.2%+9.1pp
Return on Equity	5.4%+0.9pp	1.6%+1.3pp	5.7%+5.6pp	4.4%+0.2pp	4.5%+0.1pp	0.3%-1.3pp	0.1%-5.9pp	4.2%+2.5pp
Return on Assets	0.8%+0.2pp	0.2%+0.2pp	0.9%+0.9pp	0.6%0.0pp	0.6%0.0pp	0.0%-0.2pp	0.0%-0.8pp	0.6%+0.4pp
Debt-to-Equity	5.71+4.0x	1.29-0.5x	1.14-0.3x	1.34-4.7x	1.67-4.7x	1.820.0x	1.470.0x	5.99+4.3x
Asset Turnover	0.050.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.040.0x	0.050.0x	0.040.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Current Ratio, FCF Margin.

Where BFHIV Ranks

Frequently Asked Questions

What is BFHIV's annual revenue?

BFHIV (BFHIV) reported $3.8B in total revenue for fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BFHIV's revenue growing?

BFHIV (BFHIV) revenue grew by 0.2% year-over-year, from $3.8B to $3.8B in fiscal year 2025.

Is BFHIV profitable?

Yes, BFHIV (BFHIV) reported a net income of $518.0M in fiscal year 2025, with a net profit margin of 13.5%.

How much debt does BFHIV have?

As of fiscal year 2025, BFHIV (BFHIV) had $3.6B in cash and equivalents against $4.3B in long-term debt.

What is BFHIV's net profit margin?

BFHIV (BFHIV) had a net profit margin of 13.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does BFHIV pay dividends?

Yes, BFHIV (BFHIV) paid $0.86 per share in dividends during fiscal year 2025.

What is BFHIV's return on equity (ROE)?

BFHIV (BFHIV) has a return on equity of 15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BFHIV's operating cash flow?

BFHIV (BFHIV) generated $2.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BFHIV's total assets?

BFHIV (BFHIV) had $22.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Does BFHIV buy back shares?

Yes, BFHIV (BFHIV) spent $313.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does BFHIV have outstanding?

BFHIV (BFHIV) had 43M shares outstanding as of fiscal year 2025.

What is BFHIV's debt-to-equity ratio?

BFHIV (BFHIV) had a debt-to-equity ratio of 1.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BFHIV's return on assets (ROA)?

BFHIV (BFHIV) had a return on assets of 2.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BFHIV's Piotroski F-Score?

BFHIV (BFHIV) has a Piotroski F-Score of 7 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BFHIV's earnings high quality?

BFHIV (BFHIV) has an earnings quality ratio of 4.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.